Particle.news
Download on the App Store
3 ARTICLES
·
15h ago

XJ-4-85 Forces Metabolic Collapse in Tumors

The study presents electrophile‑drug conjugates as a small, fully chemical method to hit intracellular cancer targets and simplify manufacture.

PFKL is an enzyme in cancer cells that metabolizes sugar. This image shows the protein structure of PFKL bound to two parts of the experimental cancer drug XJ-4-85 (blue and orange). When XJ-4-85 binds the sites K677 and K315 on PFKL (inset), it boosts sugar metabolism and releases a payload (not shown) that shuts down fatty acid metabolism. Credit: Eric Lynch (University of Washington) and Xiaoding Jiang (University of Texas at Austin)

Overview

  • A peer‑reviewed paper published Aug. 5 in Nature Chemical Biology reports that researchers at The University of Texas at Austin designed the two‑part molecule XJ‑4‑85 and tested it in cells and mice.
  • XJ‑4‑85 covalently binds the glycolysis enzyme PFKL at lysines K677 and K315 to hyperactivate sugar breakdown and then releases a payload that inhibits CPT2, the enzyme that helps cells burn fatty acids.
  • In lab tests the compound killed multiple human cancer cell types and produced widespread tumor cell death in a mouse model of aggressive melanoma while having a smaller effect on nearby noncancerous cells.
  • The team frames the approach as a new class called electrophile‑drug conjugates (EDCs), which are small, fully chemical counterparts to antibody‑drug conjugates and can access targets inside cells and be easier to make.
  • The work is early and preclinical, and investigators say more lab studies are needed to define safety, tissue specificity, drug behavior in animals, and potential resistance before any human trials can be considered.